Drugs / SELODENOSON
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00040001 | — | atrial fibrillation | Aderis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SELODENOSON | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107371 ↗ |
| Known as | DTI-0009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00040001 ↗ |
| Known as | GR-56072 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107371 ↗ |
| Known as | RG-14202 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107371 ↗ |
| Action | Activate | “Adenosine A1 receptor agonist” CHEMBL2107371 ↗ |
| Modality | Small molecule | — CHEMBL2107371 ↗ |
| Target | ADORA1 | “Adenosine A1 receptor agonist” CHEMBL2107371 ↗ |